Leerink Partners Forecasts Strong Price Appreciation for AbbVie (NYSE:ABBV) Stock

AbbVie (NYSE:ABBV) had its target price raised by stock analysts at Leerink Partners from $309.00 to $342.00 in a research report issued on Monday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners‘s price objective suggests a potential upside of 18.07% from the company’s current price.

Several other brokerages have also recently weighed in on ABBV. Bank of America reaffirmed a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. BNP Paribas Exane boosted their target price on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. UBS Group restated a “neutral” rating and set a $295.00 price target on shares of AbbVie in a research report on Monday. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Finally, JPMorgan Chase & Co. lifted their price target on AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a report on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $293.29.

AbbVie Stock Performance

Shares of NYSE:ABBV traded down $5.22 on Monday, hitting $289.67. The stock had a trading volume of 5,404,959 shares, compared to its average volume of 6,324,456. The firm’s 50 day moving average price is $269.35 and its 200-day moving average price is $237.23. AbbVie has a twelve month low of $190.75 and a twelve month high of $298.74. The company has a market capitalization of $511.78 billion, a price-to-earnings ratio of 49.72, a price-to-earnings-growth ratio of 1.35 and a beta of 0.24.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 435.41%. The business had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. During the same quarter last year, the company posted $1.86 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. As a group, sell-side analysts predict that AbbVie will post 13.92 EPS for the current year.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On AbbVie

Several institutional investors have recently modified their holdings of the business. State Street Corp boosted its stake in AbbVie by 1.7% in the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after buying an additional 106,091 shares during the period. Legal & General Group Plc bought a new position in shares of AbbVie during the second quarter worth about $2,905,952,000. Deutsche Bank AG grew its holdings in shares of AbbVie by 13.0% during the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock worth $2,710,905,000 after buying an additional 1,241,587 shares in the last quarter. Finally, Amundi raised its position in AbbVie by 2.4% in the 1st quarter. Amundi now owns 10,698,095 shares of the company’s stock valued at $2,326,728,000 after buying an additional 247,689 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s third-quarter revenue reached $17.4 billion, ahead of expectations, while earnings also surpassed estimates. Growth from immunology drugs Skyrizi and Rinvoq is more than offsetting Humira’s erosion, helping the company raise its 2026 revenue and adjusted earnings outlook. AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
• Positive Sentiment: Analysts responded to the results by raising their targets. Morgan Stanley increased its target to $346 and maintained an “overweight” rating; RBC raised its target to $330 with an “outperform” rating; and Canaccord Genuity and Cantor Fitzgerald lifted targets to $338 and $325, respectively. Analysts Increase Their Forecasts on AbbVie After Strong Q3 Results
• Positive Sentiment: The company increased its quarterly dividend by 5.2% to $1.82 per share, or $7.28 annualized. The higher payout reinforces AbbVie’s appeal to income-focused investors and signals management’s confidence in cash-flow generation.
• Positive Sentiment: Pipeline developments provide a longer-term growth opportunity. AbbVie’s experimental ABBV-466 nearly doubled Skyrizi’s Crohn’s disease remission rate in a Phase 2 study, potentially supporting a future follow-on blockbuster. AbbVie’s Next Blockbuster Is Hiding in a Two-Drug Crohn’s Combo
• Neutral Sentiment: Investors are assessing whether Skyrizi, Rinvoq, neuroscience products and pipeline candidates can sustain growth as AbbVie transitions away from its former Humira-driven revenue base. ABBV Q3 Earnings Call Highlights
• Negative Sentiment: Humira’s decline remains a structural headwind, while AbbVie’s elevated earnings multiple leaves less room for execution disappointments or slower growth. The stock’s recent decrease may therefore reflect profit-taking after its strong run, despite favorable fundamentals.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.